Research group Domschke
Experimental Psychiatry and Psychotherapy| Research group leader: | Univ.-Prof. Dr. Dr. Katharina Domschke, M.A. (USA) Phone: +49 (0)761 270 - 65060 Email: katharina.domschke@uniklinik-freiburg.de |
| Secretariat: | Angelika Pawik-Stöhr Phone: +49 (0)761 270 – 69844 Email: angelika.pawik.stoehr@uniklinik-freiburg.de |
| Group members: | Marie Basters, psychologist Pauline Beckmann, psychol. psychotherapist Marco Ell, biologist Thilo Fleisch, psychol. psychotherapist Dr. Elisabeth Hummel, biologist Hanna Lehr, psychologist Liliana Lorenz, technician Wiebke Münkel, psychologist Linda Ngeth, study nurse Jasmin Peifer, psychologist Luisa Sillmann, psychologist Marco Volkmann, study nurse Ute Wering, technician Dr. Lea Zillich, psychologist |
Research focus
Our group investigates the pathogenesis, treatment, and prevention of stress-associated and emotional mental disorders, particularly anxiety, mood and obsessive-compulsive disorders, by combining clinical and neurobiological, particularly (epi)genetic, research in a multi-level approach.
State and trait markers of mental disorders and their intermediate phenotypes
In accordance with the vulnerability-stress model of mental disorders, a multitude of interacting factors play a crucial role in their pathogenesis and maintenance. Gaining a better understanding of the state and trait markers associated with mental disorders, their clinical subtypes and symptom dimensions is of utmost importance for advancing diagnostic, prognostic and therapeutic options, which are therefore investigated by our group.
Treatment outcome prediction and personalized treatment of mental disorders
While highly effective psychotherapeutic as well as pharmacological treatment options are available, not all patients respond to the first-line treatments in a clinically meaningful way. A precise prediction of individual treatment response offers the chance to optimize individual treatment selection early on. Our research focuses on synthesizing clinical, psychological, neurobiological and environmental information in an effort to determine and investigate personalized treatment options for the individual patient.
Mechanisms of action underlying successful behavioral change through psychotherapy
Cognitive behavioral therapy (CBT) is considered the gold standard for the psychotherapeutic treatment of many mental disorders. However, the precise mechanisms of action mediating psychotherapeutic outcome are still poorly understood. Therefore, employing a multi-level approach, our aim is to identify correlates and putative mechanisms of clinical change occurring over the course of psychotherapy.
Our laboratories
Methodologically, the group combines molecular biological and clinical research methods.
On a neurobiological level, the group runs a Molecular Biological Laboratory fully equipped to perform versatile and rapid genotyping, DNA methylation analyses (pyrosequencing, direct sequencing) and analysis of histone modification such as acetylation and methylation (ChIP, qPCR).
Clinically, the group maintains a dedicated research outpatient clinic for anxiety disorders and operates a state-of-the-art Virtual Reality Laboratory. One main scientific focus is the implementation and development of psychotherapeutic interventions in VR in order to establish innovative, VR-based treatment approaches accompanied by psychoneurobiological research.
Research projects
- Targetable epigenetic, physiological and neuroimaging risk markers of anxiety sensitivity - A developmental, cross-disorder prevention study of separation anxiety and panic disorder (SFBTRR-58, project C02)
- Gene-environment interactions, neural circuits and generalization in dimensional endophenotypes of anxiety in adults and children: Development and reversibility (SFBTRR-58, project Z02)
- (Epi)genetic effects related to extinction learning and outcome (PROTECT-AD, project P5)
- Therapyepigenetics of Obsessive-Compulsive Disorder (EQUIP Medical Scientist Funding, Faculty of Medicine, University of Freiburg)
- Epigenetic risk markers as well as predictors and mechanisms of psychotherapy in acrophobia: spotlighting the BDNF system (DFG)
Selected publications
Reviews
- Schiele MA, Fagan HA, Baldwin DS, Domschke K. Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders. Psychother Psychosom. 2025 Sep 14:1-34. doi: 10.1159/000547926.
- Domschke K, Seuling PD, Schiele MA, Bandelow B, Batelaan NM, Bokma WA, Branchi I, Broich K, Burkauskas J, Davies SJC, Dell'Osso B, Fagan H, Fineberg NA, Furukawa TA, Hofmann SG, Hood S, Huneke NTM, Latas M, Lidbetter N, Masdrakis V, McAllister-Williams RH, Nardi AE, Pallanti S, Penninx BWJH, Perna G, Pilling S, Pini S, Reif A, Seedat S, Simons G, Srivastava S, Steibliene V, Stein DJ, Stein MB, van Ameringen M, van Balkom AJLM, van der Wee N, Zwanzger P, Baldwin DS (2024) The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline. World Psychiatry 23:113-123.
- Ell MA, Schiele MA, Iovino N, Domschke K (2024) Epigenetics of fear, anxiety and stress - focus on histone modifications. Curr Neuropharmacol 22:843-865.
- Seuling PD, Czernin NS, Schiele MA (2024) Virtual reality exposure therapy in the treatmant of public speaking anxiety and social anxiety disorder. Neuroscience Applied:104074.
- Schiele MA, Bandelow B, Baldwin DS, Pini S, Domschke K (2020) A neurobiological framework of separation anxiety and related phenotypes. Eur Neuropsychopharmacol 33:45-57.
- Schiele MA, Gottschalk MG, Domschke K (2020) The applied implications of epigenetics in anxiety, affective and stress-related disorders - a review and synthesis on psychosocial stress, psychotherapy and prevention. Clin Psychol Rev 77:101830.
- Schiele MA, Domschke K (2018) Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. Genes Brain Behav 17:e12423.
Original articles
- Zillich L, Czernin NS, Salvador OC, Hummel EM, Pauli P, Reif A, Deckert J, Domschke K, Schiele MA (2025) Acute stress induces changes in epigenome-wide DNA methylation. Neuropsychopharmacology doi: 10.1038/s41386-025-02289-8.
- Domschke K, Schiele MA, Crespo Salvador Ó, Zillich L, Lipovsek J, Pittig A, Heinig I, Ridderbusch IC, Straube B, Richter J, Hollandt M, Plag J, Fydrich T, Koelkebeck K, Weber H, Lueken U, Dannlowski U, Margraf J, Schneider S, Binder EB, Ströhle A, Rief W, Kircher T, Pauli P, Hamm A, Arolt V, Hoyer J, Wittchen HU, Erhardt-Lehmann A, Köttgen A, Schlosser P, Deckert J (2025) Epigenetic markers of disease risk and psychotherapy response in anxiety disorders - a longitudinal analysis of the DNA methylome. Mol Psychiatry. 30:4529-4542.
- Schiele MA, Crespo Salvador O, Lipovsek J, Schwarte K, Schlosser P, Zwanzger P, Arolt V, Baune BT, Köttgen A, Domschke K (2024) Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response? Int J Neuropsychopharmacol 27:pyae045.
- Schiele MA, Reif A, Lin J, Alpers GW, Andersson E, Andersson G, Arolt V, Bergström J, Carlbring P, Eley TC, Esquivel G, Furmark T, Gerlach AL, Hamm A, Helbig-Lang S, Hudson JL, Lang T, Lester KJ, Lindefors N, Lonsdorf TB, Pauli P, Richter J, Rief W, Roberts S, Rück C, Schruers KRJ, Thiel C, Wittchen H-U, Domschke K, Weber H, Lueken U (2021) Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis. Eur Neuropsychopharmacol 44:105-120.
- Schiele MA, Thiel C, Kollert L, Fürst L, Putschin L, Kehle R, Hauke W, Mahr M, Reinhold E, Gottschalk MG, Heinrichs M, Zaudig M, Berberich G, Domschke K (2021) Oxytocin receptor gene DNA methylation – a biomarker of treatment response in obsessive-compulsive disorder? Psychother Psychosom 90:57-63.
- Schiele MA, Zwanzger P, Schwarte K, Arolt V, Baune BT, Domschke K (2021) Serotonin transporter gene promoter hypomethylation as a predictor of antidepressant treatment response in major depression – a replication study. Int J Neuropsychopharmacology 24:191-199.
- Schiele MA, Herzog K, Kollert L, Schartner C, Leehr EJ, Böhnlein J, Repple J, Rosenkranz K, Lonsdorf TB, Dannlowski U, Zwanzger P, Reif A, Pauli P, Deckert J, Domschke K (2020) Extending the vulnerability-stress model of mental disorders: three-dimensional NPSR1 × environment × coping interaction study in anxiety. Br J Psychiatry 217:645-650.
- Schiele MA, Thiel C, Deckert J, Zaudig M, Berberich G, Domschke K (2020) Monoamine oxidase A hypomethylation in obsessive-compulsive disorder - reversibility by successful psychotherapy? Int J Neuropsychopharmacol 23:319-323.
- Ziegler C, Grundner-Culemann F, Schiele MA, Schlosser P, Kollert L, Mahr M, Gajewska A, Lesch KP, Deckert J, Köttgen A, Domschke K (2019). The DNA methylome in panic disorder: a case-control and longitudinal psychotherapy-epigenetic study. Transl Psychiatry 9:314.
- Schiele MA, Ziegler C, Kollert L, Katzorke A, Schartner C, Busch Y, Gromer D, Reif A, Pauli P, Deckert J, Herrmann MJ, Domschke K (2018). Plasticity of functional MAOA gene methylation in acrophobia. Int J Neuropsychopharmacol 21:822-827.
Funding
- Deutsche Forschungsgemeinschaft (DFG)
- Bundesministerium für Bildung und Forschung (BMBF), PROTECT-AD
- European Union (EU), EUSARNAD, FP7-PEOPLE-2010-IRSES
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Würzburg
- EQUIP Medical Scientist Funding, Medical Faculty, University of Freiburg
- Forschungskommission der Medizinischen Fakultät, Universität Freiburg
Cooperations and Networks
- DFG Sonderforschungsbereich SFB/Transregio 58 "Furcht, Angst, Angsterkrankungen"
- BMBF Forschungsverbund PROTECT-AD
- Gesellschaft für Angstforschung (GAF)
- Anxiety Disorders Research Network (ADRN), European College of Neuropsychopharmacology (ECNP)
- Obsessive Compulsive and Related Disorders Network (OCRN), European College of Neuropsychopharmacology (ECNP)
- Prevention of Mental Disorders and Mental Health Promotion Network, European College of Neuropsychopharmacology (ECNP)
- Thematic Working Group on Resilience, European College of Neuropsychopharmacology (ECNP)
